Gimatecan

吉马替康

Report date: 2024/02/06 16:32:16
NME

Base Information

Drug NameGimatecan
Drug Alias NameLBQ-707CPT-184NVP-LBQ707ST-1481
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursMyelodysplastic Syndromes +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSigma-Tau Spa
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesZhaoke (Guangzhou) Oncology Pharmaceutical Ltd
Inactive CompaniesLee'S Pharmaceutical LtdSigma-Tau Research IncNovartis Pharma Ag +[5] 
Active IndicationsFallopian Tube NeoplasmsSmall Cell Lung CarcinomaPeritoneal Neoplasms +[4] 
Inactive IndicationsCNS Embryonal TumorSolid tumoursMyelodysplastic Syndromes +[6] 

Other Information

ATC CodeN/A
Related LinksDrugBank